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Abstract
Background: ATP8A2 mutations have recently been described in several patients with severe, early-onset hypotonia
and cognitive impairment. The aim of our study was to characterize the clinical phenotype of patients with ATP8A2
mutations.
Methods: An observational study was conducted at multiple diagnostic centres. Clinical data is presented
from 9 unreported and 2 previously reported patients with ATP8A2 mutations. We compare their features with
3 additional patients that have been previously reported in the medical literature.
Results: Eleven patients with biallelic ATP8A2 mutations were identified, with a mean age of 9.4 years (range
2.5–28 years). All patients with ATP8A2 mutations (100%) demonstrated developmental delay, severe hypotonia
and movement disorders, specifically chorea or choreoathetosis (100%), dystonia (27%) and facial dyskinesia (18%).
Optic atrophy was observed in 78% of patients for whom funduscopic examination was performed. Symptom onset in
all (100%) was noted before 6 months of age, with 70% having symptoms noted at birth. Feeding difficulties were
common (91%) although most patients were able to tolerate pureed or thickened feeds, and 3 patients required
gastrostomy tube insertion. MRI of the brain was normal in 50% of the patients. A smaller proportion was noted to
have mild cortical atrophy (30%), delayed myelination (20%) and/or hypoplastic optic nerves (20%). Functional studies
were performed on differentiated induced pluripotent cells from one child, which confirmed a decrease in ATP8A2
expression compared to control cells.
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Conclusions: ATP8A2 gene mutations have emerged as the cause of a novel neurological phenotype characterized by
global developmental delays, severe hypotonia and hyperkinetic movement disorders, the latter being an important
distinguishing feature. Optic atrophy is common and may only become apparent in the first few years of life,
necessitating repeat ophthalmologic evaluation in older children. Early recognition of the cardinal features of this
condition will facilitate diagnosis of this complex neurologic disorder.
Keywords: ATP8A2, Phospholipid transfer protein, Optic atrophy, Chorea, Choreoathetosis, Dystonia, Developmental
disabilities, Whole exome sequencing
Background
P4-ATPases are a group of proteins that actively transport
phospholipids across cell membranes, a process known as
‘flipping’ [1, 2]. The main structural phospholipids
are distributed in a non-random manner across the
lipid bilayer [3], which is essential for a range of
functions including vesicle trafficking, cellular signaling
and neuronal cell survival [4]. Although 14 P4-ATPases
(flippases) have been identified, only two genes (ATP8A2
and ATP8B1) have been associated with human dis-
ease [1, 5].
ATP8A2 is highly expressed in the brain, spinal cord,
retina and testis [6, 7]. Mutations in ATP8A2 were ini-
tially identified in a family with a clinical phenotype of
cerebellar ataxia, mental retardation and disequilibrium
(CAMRQ syndrome) [8]. More recently, ATP8A2 has
been linked to a phenotype of intellectual disability, severe
hypotonia, chorea and optic atrophy without obvious
radiographic evidence of cerebellar atrophy [6, 9, 10].
We provide a clinical summary of 9 previously unre-
ported patients with ATP8A2 mutations identified via
whole exome sequencing. Detailed clinical information
is also provided for 2 previously reported patients.9
We compare the clinical features of these 11 individuals
with three additional published patients [6, 8, 10]. Ex-
pression studies of differentiated induced pluripotent
cells from one patient revealed decreased ATP8A2
RNA expression and protein levels compared to con-
trol cells.
Our observations confirm that biallelic ATP8A2 muta-
tions cause a distinct clinical phenotype that is character-
ized by global developmental delays, severe hypotonia,
optic atrophy and hyperkinetic movement disorders.
Methods
Patients
Eleven patients from nine families were recruited to par-
ticipate in this study. The Research Ethics Board of the
Hospital for Sick Children approved this study and in-
formed consent was obtained from all families according
to the Declaration of Helsinki. The family of Patient 1
consented to a skin biopsy for functional studies to be
performed.
Molecular studies
Three unrelated patients (Patients 1, 2 and 5) had exome
sequencing completed at GeneDx (Gaithersburg, MD).
Genomic DNA was extracted from whole blood from af-
fected children and their parents. Exome sequencing
was performed on exon targets captured using either the
Agilent SureSelect Human All Exon (50 Mb) V4 kit or
Clinical Research Exome kit (Agilent Technologies,
Santa Clara, CA). One microgram of DNA from periph-
eral blood was sonicated into 300 bp fragments, which
were then repaired, ligated to adaptors, and purified
for subsequent PCR amplification. Amplified products
were then captured by biotinylated RNA library baits in so-
lution following the manufacturer’s instructions. Bound
DNA was isolated with streptavidin-coated beads and
re-amplified. The final isolated products were sequenced
using either the Illumina HiSeq 2500 or 4000 sequencing
system with either 2 × 100-bp or 2 × 150-bp paired-end
reads (Illumina, San Diego, CA). DNA sequence was
mapped to the published human genome build UCSC
hg19/GRCh37 reference sequence using BWA-Mem
v0.7.8 [11]. Targeted coding exons and splice junctions of
known protein-coding RefSeq genes were assessed for
average depth of coverage with a minimum depth of 10X
required for inclusion in downstream analysis. Local re-
alignment around insertion-deletion sites was performed
using the Genome Analysis Toolkit v2.3 [12]. Variant calls
were generated simultaneously on all sequenced family
members using either Samtools 0.1.18 or Samtools 0.1.18
along with GATK 2.3 HaplotypeCaller [11, 12]. All coding
exons and surrounding intron/exon boundaries were
analyzed. CNVs were called as previously described [13].
Automated filtering removed common sequence changes
(defined as > 10% frequency present in the 1000 Genomes
database). The targeted coding exons and splice junctions
of the known protein-coding RefSeq genes were assessed
for the average depth of coverage and data quality threshold
values. Whole exome sequence data for all sequenced fam-
ily members was analyzed using GeneDx’s XomeAnalyzer
(a variant annotation, filtering, and viewing interface for
WES data), which includes nucleotide and amino acid an-
notations, population frequencies (NHLBI Exome Variant
Server and 1000 Genomes databases), in silico prediction
McMillan et al. Orphanet Journal of Rare Diseases  (2018) 13:86 Page 2 of 10
tools and amino acid conservation scores (Mutation Taster,
PhyloP, and CADD). Variants were filtered based on in-
heritance patterns, gene lists of interest, phenotype,
and population frequencies, as appropriate. Resources in-
cluding the Human Gene Mutation Database (HGMD),
1000 Genomes database, NHLBI Exome Variant Server,
OMIM, PubMed, and ClinVar were used to evaluate genes
and sequence changes of interest [14–17]. Identified se-
quence changes of interest were confirmed in all family
members by di-deoxy Sanger sequence analysis using an
ABI3730 (Life Technologies, Carlsbad, CA) and standard
protocols with a new DNA preparation. CNVs were con-
firmed in relevant family members by whole genome or
exon-focused oligonucleotide array-based comparative
genomic hybridization (Agilent Technologies, Santa Clara,
CA), quantitative polymerase chain reaction, or multiplex
ligation-dependent amplification. Patient 3 underwent
exome sequencing at BGI, Denmark with subsequent
annotation and interpretation at the Genome Diagnos-
tics laboratory in Nijmegen, the Netherlands. Libraries
were prepared using Agilent SureSelect Human All
Exon enrichment kit version 5 (Agilent Technologies)
and sequenced on an Illumina HiSeq4000 2x150bp.
Reads were aligned to hg19 reference genome using
BWA − 0.7.8-r455, variants were called with GenomeAna-
lysisTK 3.3–0-g37228af and annotated using an in-house
pipeline. Exome sequencing for Patient 4 was carried out in
the molecular laboratory of the Hôpital Pitié-Salpêtrière
in Paris, France. Libraries were prepared from genomic
DNA using Roche SeqCap MedExome kits and se-
quenced on an Illumina NextSeq 500 2x150bp high
output (with 12 plexes). Reads were aligned to hg19 ref-
erence genome using BWA-mem, variants were called
with GenomeAnalysisTK-2014.3-17-g0583018 and an-
notated using SNPEff-4. Custom scripts were utilized
for variant filtration and prioritization. Exome sequen-
cing for Patients 6 and 7 was carried out at Novogene
using the Agilent SureSelect V6 enrichment kit with a
paired-end (150 bp) protocol at a mean coverage of
50X. Reads were aligned to genome assembly hg19
with the Burrows-Wheeler Aligner (BWA) (Version
0.7.8-r455). Exome sequencing for Patients 8 and 9 was
carried out at the Institute for Molecular Bioscience in
Queensland, Australia. Libraries were prepared from gen-
omic DNA using Nextera Rapid Capture Exome kits and
sequenced on an Illumina HiSeq 2000 to a minimum aver-
age coverage of 95X. Reads were aligned to hg19 reference
genome using BWA-mem, variants were called with
GATK HaplotypeCaller v3.7 and annotated using SnpEff
v4.3 m. Custom scripts were utilized for variant filtration
and prioritization. Patients 10 and 11 were diagnosed at
12 de Octubre Hospital in Madrid, Spain and have been
previously reported [9]. Detailed exome sequencing
methods are outlined in Additional file 1: Table S1.
Functional studies
Human pluripotent stem cell differentiations
Human induced pluripotent stem cells (iPSCs) were gen-
erated from control and patient fibroblasts, differenti-
ated into endodermal lineage cells, and cell lysates were
used to quantify RNA expression and concentration of
ATP8A2 protein.
The human iPSCs were generated in house from BJ fi-
broblasts (ATCC) or patient fibroblasts by infecting with
Sendai virus as outlined in the manufacturer’s protocol
(Cytotune 2.0; LifeTechnologies). Cells were plated on
Matrigel (Corning) after 48 h and subsequently transi-
tioned to mTeSR-E8 media (StemCell Technologies) from
days 4–7 post-infection. At 3 weeks post-infection, iPSC
clones were picked into and maintained in mTeSR-E8 on
Matrigel-coated 96-well plates. Clones were passaged
using ReLeSR (Stem Cell Technologies) every 4–6 days
until passage 15. Sendai virus transgene expression was
then analyzed, and found to be absent, using Taqman
(Life Technologies) and pluripotency markers assessed
by immunostaining and qPCR.
hIPSCs were plated onto geltrex (1:100)-coated 12 well
plates at a density of 0.5 × 106 in 10/10 media [DMEM/
F12, KOSR, Glutamax, P/S, 10 ng/mL Activin A (E-bio-
sciences) and 10 ng/mL herugulin (Tocris) [18]. Differ-
entiations began 48 h post-seeding using a modified
version of Rezania et al. [19]. Briefly, cells were rinsed
with 1× DPBS (Mg2+ and Ca2+ free) and then basal cul-
ture media (MCDB 131 medium, 1.5 g/l sodium bicar-
bonate, 1× Glutamax, 1× P/S) with 10 mM final glucose,
0.5% BSA, 100 ng/ml Activin A (E-biosciences), and
3 μM of CHIR-99021 (Sigma) was added for 1 day only.
For the following two days, cells were treated with the
same media without CHIR-99021 compound to generate
definitive endoderm (Stage 1). On day four, cells were
cultured in basal media with 0.5% BSA, 10 mM glucose,
0.25 mM ascorbic acid (Sigma) and 50 ng/ml of KGF
(R&D Systems) for 2 days to generate primitive gut tube
(Stage 2). To produce posterior foregut (Stage 3), cells
were treated for three days with basal media with
10 mM final glucose concentration, 2% BSA, 0.25 mM
ascorbic acid, 50 ng/ml of KGF, 0.25 μM SANT-1
(Tocris Biosciences), 1 μM retinoic acid (Sigma), 100 nM
LDN193189 (EMD Millipore), 1:200 ITS-X (Gibco), and
200 nM TPB (EMD Millipore).
qPCR
Cells were lysed in Trizol and standard phenol-chloroform
extraction was used to isolate RNA as previously described
[20]. Following RNA extraction, Superscript III was
used for reverse transcription followed by Taqman on
ViiA7 384-well thermocycler. Fluorogenic probes used
included FAM and the IowaBlack non-fluorescent
quencher (PrimeTime; IDT). Primer/probe sequences
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are: 1) ATP8A2, Primer-1 TGGTTCCTACTGCCTGTTT
G; Primer-2 CCTCTTTCCATTGCTATCCCG; Probe
CTTGGTTTCCAGCTCCTGCACCT. 2) TBP, Primer-1
GAGAGTTCTGGGATTGTACCG; Primer-2 ATCCTCA
TGATTACCGCAGC; Probe TGGGATTATATTCGGCG
TTTCGGGC.
Protein analysis and western blotting
Cells were lysed in Laemmeli buffer (2% SDS, 10% gly-
cerol, 5% 2-mercaptoethanol, and 0.068 M Tris HCl,
pH 6.8) in the absence of bromophenol blue. The solu-
tion was boiled for 10 min. The DNA was sheared by
passing the sample through a 26 gauge needle followed
by sonication. The sample was then centrifuged for
10 min at 1000 g and the supernatant was retained for
protein concentration determination using the Bradford
Protein Assay and analysis by SDS gel electrophoresis
and Western blotting.
For western blotting, proteins were transferred on to
Immobilon FL membranes (Millipore, Bedford, MA)
using a BioRad semi-dry transfer apparatus. The blots
were blocked with 1% milk in PBS for 30 min and subse-
quently labeled with ATP8A2 polyclonal antibody [21]
and actin polyclonal (ab8227, Abcam) antibody as a
loading control. The ATP8A2 and actin antibodies were
diluted to a concentration of 0.3 mg/ml and 0.2 mg/ml,
respectively in PBS containing 0.05% Tween 20 (PBST).
The blots were incubated with primary antibodies for
1 h, washed with PBST, and subsequently incubated for
40 min. With secondary antibody (goat anti-rabbit Ig
conjugated with horseradish perioxidase (Sigma) diluted
1:20,000 in PBST containing 0.1% milk) and washed
with PBST prior to detection by ECL. The film was
scanned on a LiCor imager and the intensity of the
ATP8A2 labeled bands was quantified using Image
Studio Lite software.
Results
Clinical features
The clinical features of individuals with ATP8A2 muta-
tions are described for 11 patients ranging from 2.5 years
to 28 years (Table 1). Patients were of varied ethnicities
with 8/11 (73%) demonstrating parental consanguinity.
All patients exhibited severe hypotonia at or within
6 months after birth which persisted, with older children
and adults being unable to achieve head control and/or
sit independently (Table 2). Expressive and receptive lan-
guage skills were impaired in all patients. Most children
(9/11, 82%) did not develop any meaningful speech, with
only two communicating with mono or di-syllabic
words, or with the aid of pictograms (Table 2). Hyper-
kinetic movement disorders, specifically chorea or chor-
eoathetosis were present in all patients (Additional file 2:
Video S1; Additional file 3: Video S2). Dystonia and/or
facial dyskinesia were noted in a smaller proportion of
patients (Additional file 4: Video S3). Feeding difficulties
were a significant feature of our cohort and were re-
ported in 10/11 (91%) individuals. All 10 patients re-
quired modified feeds such as pureed or thickened feeds,
and all required significant assistance with feeding.
Three patients (Patients 1, 2 and 9) required gastros-
tomy tubes due to their risk of aspiration when drinking
thin liquids. Weight was below the third percentile for
70% (7/10) of the patients who had a recent weight
available. Occipitofrontal head circumference (OFC) was
within the normal range for the majority of patients, and
5/11 (45%) had OFC at or below the second percentile
for age. Optic atrophy was noted in 7/9 (78%) patients
who underwent funduscopic examination. The two chil-
dren who did not have optic atrophy did not have testing
of visual evoked potentials. In one child (Patient 1) who
underwent repeat funduscopic examinations, optic atro-
phy was noted to progress in the first few years of life.
Initial ophthalmology examination at 10 months was en-
tirely normal including funduscopic examination, and
the patient had normal visual fixation and tracking. Re-
peat examination at 19 months revealed mild optic
nerve pallor. At 26 months she was no longer able to
visually fix or follow and optic nerve atrophy was seen.
Visual evoked potentials at 3 years revealed absentcorti-
cal responses. At 4.5 years she had severe optic nerve at-
rophy (Fig. 1) with optical coherence tomography (OCT)
showing selective thinning of the inner retinal layers. A
smaller proportion of patients exhibited ophthalmoplegia
(45%) or ptosis (36%) (Additional file 5: Video S4).
Seizures were observed in two siblings from a single fam-
ily, with the remaining 9/11 patients being seizure-free.
Patient 8 did not require treatment with anti-epileptics
and Patient 9 had seizures which were well-controlled
with valproate and carbamazepine. Neither patient had
EEG studies available for review. One patient was noted to
have abnormal brainstem auditory evoked potentials
(BAER) responses (Patient 4) consistent with sensori-
neural hearing loss. This patient also had abnormal som-
atosensory evoked potentials (SSEP) suggesting a
myelinopathy involving the dorsal column of the spinal
cord. One other patient (Patient 5) was noted to have ab-
normal hearing.
Nerve conduction studies and electromyography was
performed on 8/11 patients with no evidence of a sen-
sorimotor neuropathy observed (Table 3). Single fiber
EMG was normal in one patient who had ptosis. Neuro-
imaging was performed in all but one patient. MRI of
the brain revealed no intracranial abnormalities in
50% (5/10) patients (Table 3). Non-specific findings
included mild cerebral or cortical atrophy (30%), mild
delay in myelination (20%), thin corpus callosum
(20%) or hypoplastic optic nerves (20%). Additional
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detailed clinical information is provided for Patients 1
and 3 as Additional file 6.
Genetic testing
Biallelic ATP8A2 gene mutations were identified in all af-
fected individuals, consistent with autosomal recessive in-
heritance (Table 4). Carrier parents were asymptomatic.
Identified genetic variants included missense, splicing, in-
tragenic deletions, and frameshift mutations, which were
predicted to cause loss of function of ATP8A2, and were
not present in the homozygous state in the Exome Aggre-
gation Consortium (ExAC) public database or our internal
exome databases of unaffected individuals. All variants oc-
curred within highly conserved domains, and were pre-
dicted to be damaging or possibly damaging by multiple
in silico models (SIFT, Polyphen, MetaSVM, MetaSVM,
Mutation Taster, PhyloP, and CADD).
Functional studies
Initial studies were unable to detect any ATP8A2 in the
control or fibroblasts from Patient 1, due to low ATP8A2
expression in this tissue. Subsequent reprogramming of
the fibroblasts into induced pluripotent cells allowed der-
ivation of tissues that expressed higher amounts of
ATP8A2 to enable study. We found that early endoderm
derivatives expressed high levels of ATP8A2 and allowed
analyses of RNA expression and ATP8A2 protein expres-
sion. To ensure that the patient’s cells could differentiate
into endoderm with equivalent efficiency as control cells,
we assessed expression of two endoderm markers, FOXA2
and SOX17. Using expression of these markers, the pa-
tient’s cells more readily adopted the endoderm fate com-
pared to control cells (Supplementary Figure S1). ATP8A2
mRNA expression was significantly lower in the patient
compared to control cells and there was diminished
ATP8A2 protein in the patient cells, confirming the dele-
terious effect of the mutations (Fig. 2). From these studies
we conclude this patient had loss of function mutations in
ATP8A2, which likely improved endoderm differentiation.
Discussion
Despite the critical role of P4-ATPase proteins in normal
cellular functioning, they have only recently been implicated
in human disease. Whole exome sequencing continues to
Table 1 Clinical characteristics of individuals with ATP8A2 mutations
Patients 1 2 3 4 5 6 7 8 9 10 11 Totala
Gender F F F F M F M M F F F
Symptom onset Birth Birth Birth Birth 6 mos 4 mos Birth 6 mos Birth Birth 1 mos
Current age (years) 5y 2.5y 2.7y 6y 5y 9y 15y 16yb 28y 8.5y 5.5y
Gestational age (wk) 40 39 41 40 39 39 40 40 Term 40 39
Birth weight (kg) 4.14 3.57 3.09 4.55 2.62 2.70 2.90 N/a N/a 3.19 2.87
Clinical features
Hypotonia onset Birth Birth Birth Birth Infancy Infancy Birth Infancy Birth Birth Infancy
Hypotonia persists? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 100%
Muscle weakness Yes Yes Yes N/a No Yes Yes N/a N/a Yes Yes 80%; 8/10
Optic Atrophy Yes N/a Yes Yes Yes No No Yes N/a Yes Yes 78%; 7/9
Ophthalmoplegia No No No Yes No No No Yes Yes Yes Yes 45%
Ptosis No No Yes Yes No No No No Yes No Yes 36%
Hearing Loss No No No Yes Yes No No No No No No 18%
Seizures No No No No No No No Yes Yes No No 18%
Feeding difficulties Yes, G-tube Yes, G-tube Yes No Yes Yes Yes Yes Yes, G-tube Yes Yes 91%
Sleep disturbance Yes Yes No N/a No Yes No No No No Yes 40%; 4/10
Movement disorder
Chorea or
choreoathetosis
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 100%
Dystonia Yes No Yes Yes No No No No No No Yes 36%
Facial dyskinesia No No No No No No No No No Yes Yes 18%
Current head size (OFC) 25%ile 25%ile 5%ile < 2%ile 10%ile 2%ile 15%ile < 3%ile < 2%ile 25%ile < 2%ile
Current weight 25%ile 83%ile 60%ile N/A < 3%ile < 2%ile < 2%ile < 3%ile < 2%ile < 3%ile < 3%ile
Current length/height 85%ile 90%ile 40%ile N/A 25%ile < 2%ile < 2%ile < 3%ile < 2%ile 5%ile 20%ile
aDenominator = 11 unless otherwise indicated; F female, M male, y years old, mos months old, wk weeks, N/a not available, %ile percentile, OFC occipitofrontal
head circumference, NCS/EMG nerve conduction study and electromyography, BAER brainstem auditory evoked response, bDeceased
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expand our clinical diagnostic capabilities, and in this in-
stance has permitted the delineation of a specific neurologic
phenotype associated with ATP8A2mutations.
An early report described an infant with severe hypo-
tonia and global developmental delay who was found to
have a de novo t(10;13) balanced translocation with the
breakpoint disrupting the coding sequence of a single
gene, ATP8A2 [6]. Although the authors were not able
to quantify ATP8A2 expression, they hypothesized that
the phenotype may be attributed to haploinsufficiency of
Fig. 1 a Severe bilateral optic atrophy on direct funduscopic examination. b Optical coherence tomography (OCT) reveals relatively thinning of the
inner retinal layers suggestive of optic atrophy of those neuronal elements. Outer retinal layers (OPL, ONL) are less affected. RPE = retinal pigmented
epithelium; ONL = outer nuclear layer; OPL = outer plexiform layer, RNFL = retinal nerve fiber layer; GCL = ganglion cell layer; IPL inner plexiform layer
Table 2 Best developmental achievement of individuals with ATP8A2 mutations
Patient Age (years) Language Gross motor Fine motor Feeding G-tube
1 5 Non-verbal Cannot sit Transfers hand-to-hand Requires pureed or
thicker feeds
Yes
2 2.5 Babbles Cannot sit Holds objects, not transferring Requires thickened
foods
Yes
3 2.7 Non-verbal Cannot roll or support head Attempting to grasp Requires pureed or
thicker feeds
No
4 6 Non-verbal Cannot sit Cannot grasp No issues No
5 5 Non-verbal Cannot sit Hand grasp Feeding difficulties No
6 9 Non-verbal Impaired Impaired Feeding difficulties No
7 15 Non-verbal Impaired Impaired Feeding difficulties No
8 16a None Impaired Impaired Feeding difficulties No
9 28 None Impaired Impaired Feeding difficulties Yes
10 8.5 Monosyllabic & disyllabic words Cannot support head Holds objects Requires soft foods No
11 5.5 Uses signs, pictograms Cannot support head Attempting to grasp Requires crushed
foods
No
aDeceased
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the ATP8A2 gene since a mutation on the other allele
was not identified [6]. It was not documented if this pa-
tient underwent funduscopic examination, however vis-
ual parameters at 1 year of age were reported to be
normal. Repeat visual assessment was not reported to
ascertain if, as for Patient 1 in our case series, optic atro-
phy developed later in childhood.
Four members of a consanguineous Turkish family
with cerebellar ataxia, mental retardation and disequilib-
rium (CAMRQ) syndrome who had previously been
identified by homozygosity mapping to have shared re-
gions of homozygosity on chromosomes 13, 19 and 20
underwent whole exome sequencing [8]. A homozygous
c.1128 C > G; p.I376M mutation in ATP8A2 was identi-
fied which was predicted to change the secondary struc-
ture of the ATP8A2 protein and postulated to be the
cause of the CAMRQ syndrome. Phenotypic findings
that were unique to these patients included truncal
ataxia with or without quadrupedal gait, dysarthric
speech as well as MRI evidence of mild cerebral and
cerebellar atrophy. The presence or absence of optic at-
rophy was not reported.
One additional child was identified by whole exome
sequencing to have biallelic mutations in ATP8A2 [10].
This child demonstrated severe axial hypotonia that was
noted in the first 6 months of life. At 11 years of age the
child remains non-ambulatory and is capable of speaking
single-word or short sentences with marked dysarthria.
MRI of the brain was normal. He was reported to have
choreoathetosis, dystonia and optic atrophy documented
on funduscopic examination.
ATP8A2 is responsible for maintaining a higher con-
centration of phosphatidylserine at the inner surface of
the phospholipid bilayer [7, 22]. Mouse models of
ATP8A2 deficiency have demonstrated that Atp8a2 mu-
tations result in impaired axonal transport, axonal loss,
failure to thrive and clinical manifestations of neurode-
generative disease which are similar to the patients we
describe [7]. In addition to axonal loss in the spinal cord
and retina, mice harbouring Atp8a2 loss of function mu-
tations have been found to have axonal degeneration af-
fecting peripheral nerves [7]. However, none of the
patients with ATP8A2 mutations in our cohort have
demonstrated any abnormalities on nerve conduction
studies or electromyography (NCS/EMG) (Table 1). Pa-
tient 1 underwent a sedated NCS/EMG including con-
centric needle EMG of intrinsic foot muscles with no
neurogenic changes identified. Due to her fluctuating
Table 4 Genetic characteristics of individuals with ATP8A2 mutations
Patient Ethnicity Alleles Mutations Predicted effect on protein
1 French Canadian, Algerian Compound heterozygote c.1185 + 5G > A
del exons 28–33
Destroys spice donor site in intron 12
Partial gene deletion
2 European Ashkenazi Native
American
Compound heterozygote c.1787delA
c.321 + 3_321 + 8 delAATGGT
p.Asn596MetfsX – frameshift
Destroys spice donor site in intron 3
3 Turkish Homozygousa c.1756C > T p.Arg586* - premature stop codon
4 Moroccan Homozygousa c.2104 T > C p.Trp702Arg – missense
5 Sri Lankan Homozygousa c.1286A > T p.Lys429Met – missense
6 Iranian Homozygousa c.1474_1662del (del exons 17–18) p.Pro492_Ala554del
7 Iranian Homozygousa c.1474_1662del (del exons 17–18) p.Pro492_Ala554del
8 Lebanese Homozygous c.3188_3196delCTATGGTCC insGAAGAAG p.Thr1063fs - frameshift
9 Lebanese Homozygous c.3188_3196delCTATGGTCC insGAAGAAG p.Thr1063fs - frameshift
10 Spanish Homozygousa c.1287G > T p.Lys429Asn - missense
11 Spanish, Argentinian Compound heterozygote c.1630G > C
c.1873C > T
p.Ala544Pro – missense
p.Arg625Trp - missense
aKnown consanguinity
Table 3 Ancillary testing of individuals with ATP8A2 mutations
Patient Nerve conduction MRI brain (age of study, years)
1 Normal Normal; hypoplastic optic nerves
(2 yrs., 3 yrs)
2 N/A Normal (1.5 yrs)
3 Normal Mild delay in myelination for age;
subcortical white matter volume loss,
thin corpus callosum (8 mos, 1.3 yrs)
4 Normal Normal
5 Normal Normal; hypoplastic optic nerves
6 N/A N/A
7 Normal Normal
8 Normal N/A (CT brain =mild cerebral atrophy)
9 Normal Hyperintense signal (T2FLAIR) in optic
radiations (12 yo)
10 Normal Delayed myelination for age, mild
cerebral atrophy, thin corpus
callosum (6 yrs)
11 N/A Delayed myelination in temporal
lobes (1.8 yrs)
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ptosis, Patient 3 underwent NCS with repetitive nerve
stimulation as well as EMG and stimulated single fiber
EMG with no abnormalities demonstrated. The precise
reason for this discrepant peripheral nervous system
phenotype between mouse models of ATP8A2 loss of
function mutations and our patients is unknown, and
deserves further study.
Previous work has shown that ATP8A2 is important
for function of ectoderm derivatives; however, here we
also demonstrate that ATP8A2 is also expressed in an-
other germ layer early in development. In the endoderm,
ATP8A2 appears to limit differentiation as patient de-
rived induced pluripotent cells with reduced ATP8A2
expression were more readily able to adopt the endo-
derm fate. In the future, it will be interesting to test how
ATP8A2 impacts the early embryonic development of
ectodermal germ layer in order to understand when it
becomes important for brain development.
Conclusion
This is the largest report of patients with confirmed
ATP8A2 mutations to date. Despite the variability in mu-
tation type and location, the patients in this series show
remarkable phenotypic similarity with all having profound
cognitive impairment, severe and persistent hypotonia and
chorea or choreoathetosis. The identification of the latter
feature is particularly important in distinguishing patients
with ATP8A2 mutations from the many other genetic
causes of cognitive impairment. Optic atrophy and, less
commonly, ophthalmoplegia and ptosis can also be seen
which may be helpful in establishing this diagnosis.
Feeding difficulties and failure to thrive occur frequently,
and require dietary modification and occasional interven-
tion such as G-tube placement. We suggest that this dis-
ease may be under-identified in current clinical practice,
and anticipate that increased awareness and diagnosis will
lead to a fuller appreciation of the clinical spectrum of
ATP8A2-related disorders.
Additional files
Additional file 1: Table S1. Exome sequencing of individuals with
ATP8A2 mutations. (XLSX 11 kb)
Additional file 2: Video S1. Patient 1 (age 4 years old) demonstrates
chorea of her head, upper and lower extremities characteristic of patients
with ATP8A2 mutations. (MOV 7783 kb)
Additional file 3: Video S2. Patient 7 demonstrating chorea of upper
and lower limbs. (3GP 64981 kb)
Additional file 4: Video S3. Patient 4 demonstrating dystonic posturing
of her arms. (MOV 1273 kb)
Additional file 5: Video S4. Patient 4 demonstrating chorea as well as
ptosis and ophthalmoplegia. (MOV 2274 kb)
Additional file 6: Supplementary Data - additional clinical histories.
Figure S1. Expression of FOXA2 and SOX17 in differentiated cells from
Patient 1 compared to control cells. (PDF 28 kb)
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Fig. 2 ATP8A2 expression in gut endoderm cells differentiated from patient and control fibroblasts. a ATP8A2 RNA expression levels were determined
by Taqman qPCR; data were normalized to TBP and are expressed as an average +/− SEM for n = 4. b Representative western blots of
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